The hallucinogen 2,5-dimethoxy-4-iodoamphetamine hydrochloride activates neurotrophin receptors in a neuronal cell line and promotes neurites extension View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2017-03-18

AUTHORS

Zoya Marinova, Susanne Walitza, Edna Grünblatt

ABSTRACT

Decreased neurotrophic factors expression and neurotrophin receptors signalling have repeatedly been reported in association with stress, depression, and neurodegenerative disorders. We have previously identified the hallucinogen 2,5-dimethoxy-4-iodoamphetamine hydrochloride (DOI) as protective against trophic deprivation-induced cytotoxicity in human neuroblastoma SK-N-SH cells and established the dependence of this effect on the 5-HT2A receptor, tyrosine kinases activity, and the extracellular signal-regulated kinase pathway. In the current study, we investigated the effect of DOI on tropomyosin-related kinase receptor A (TrkA) phosphorylation. Treatment with DOI increased TrkA tyrosine phosphorylation in SK-N-SH cells, determined by immunoprecipitation with TrkA antibody and immunoblotting with anti-phosphotyrosine- and TrkA-antibodies. Analysis of DOI’s effect on individual TrkA residues in SK-N-SH cells showed that it increases TrkA Tyr490 phosphorylation (177 ± 23% after 5 μM DOI for 30 min compared to vehicle). Furthermore, DOI treatment increased the percentage of SK-N-SH cells extending neurites in a TrkA-dependent manner (17.2 ± 2.2% after 5 μM DOI treatment for 6 days compared to 5.6 ± 1.7% after vehicle). In a different cell model—lymphoblastoid cell lines—DOI treatment increased tropomyosin-related kinase receptor B (TrkB) phosphorylation, determined by immunoprecipitation with TrkB antibody and immunoblotting with anti-phosphotyrosine antibody and total Trk antibody. Our results identify the Trk receptors as a downstream target of the hallucinogen DOI. In light of the known involvement of Trk receptors in mental diseases, their participation in DOI-mediated effects warrants further investigation. More... »

PAGES

749-759

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s00702-017-1706-y

DOI

http://dx.doi.org/10.1007/s00702-017-1706-y

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1084023046

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/28315978


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1109", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Neurosciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Amphetamines", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Cell Line, Tumor", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Hallucinogens", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Lymphocytes", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Nerve Growth Factor", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Neurites", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Neuronal Outgrowth", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Phosphorylation", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Receptor, Serotonin, 5-HT2A", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Receptor, Serotonin, 5-HT2B", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Receptor, trkA", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Receptor, trkB", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Serotonin 5-HT2 Receptor Antagonists", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Young Adult", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Department of Psychosomatic Medicine, Clinic Barmelweid, 5017, Barmelweid, Switzerland", 
          "id": "http://www.grid.ac/institutes/grid.452327.5", 
          "name": [
            "Department of Child and Adolescent Psychiatry and Psychotherapy, Psychiatric Hospital, University of Z\u00fcrich, Wagistrasse 12, Schlieren, 8952, Zurich, Switzerland", 
            "Department of Psychosomatic Medicine, Clinic Barmelweid, 5017, Barmelweid, Switzerland"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Marinova", 
        "givenName": "Zoya", 
        "id": "sg:person.0755076545.30", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0755076545.30"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Z\u00fcrich Center for Integrative Human Physiology, University of Z\u00fcrich, Zurich, Switzerland", 
          "id": "http://www.grid.ac/institutes/grid.7400.3", 
          "name": [
            "Department of Child and Adolescent Psychiatry and Psychotherapy, Psychiatric Hospital, University of Z\u00fcrich, Wagistrasse 12, Schlieren, 8952, Zurich, Switzerland", 
            "Neuroscience Center Z\u00fcrich, University of Z\u00fcrich and ETH Z\u00fcrich, Zurich, Switzerland", 
            "Z\u00fcrich Center for Integrative Human Physiology, University of Z\u00fcrich, Zurich, Switzerland"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Walitza", 
        "givenName": "Susanne", 
        "id": "sg:person.0736321374.53", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0736321374.53"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Z\u00fcrich Center for Integrative Human Physiology, University of Z\u00fcrich, Zurich, Switzerland", 
          "id": "http://www.grid.ac/institutes/grid.7400.3", 
          "name": [
            "Department of Child and Adolescent Psychiatry and Psychotherapy, Psychiatric Hospital, University of Z\u00fcrich, Wagistrasse 12, Schlieren, 8952, Zurich, Switzerland", 
            "Neuroscience Center Z\u00fcrich, University of Z\u00fcrich and ETH Z\u00fcrich, Zurich, Switzerland", 
            "Z\u00fcrich Center for Integrative Human Physiology, University of Z\u00fcrich, Zurich, Switzerland"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Gr\u00fcnblatt", 
        "givenName": "Edna", 
        "id": "sg:person.01126412736.07", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01126412736.07"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1385/nmm:1:3:197", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1036553133", 
          "https://doi.org/10.1385/nmm:1:3:197"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1186/1479-5876-10-239", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1023364217", 
          "https://doi.org/10.1186/1479-5876-10-239"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1186/gb-2007-8-2-r19", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1007077528", 
          "https://doi.org/10.1186/gb-2007-8-2-r19"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00018-006-6010-1", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1046148415", 
          "https://doi.org/10.1007/s00018-006-6010-1"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2017-03-18", 
    "datePublishedReg": "2017-03-18", 
    "description": "Decreased neurotrophic factors expression and neurotrophin receptors signalling have repeatedly been reported in association with stress, depression, and neurodegenerative disorders. We have previously identified the hallucinogen 2,5-dimethoxy-4-iodoamphetamine hydrochloride (DOI) as protective against trophic deprivation-induced cytotoxicity in human neuroblastoma SK-N-SH cells and established the dependence of this effect on the 5-HT2A receptor, tyrosine kinases activity, and the extracellular signal-regulated kinase pathway. In the current study, we investigated the effect of DOI on tropomyosin-related kinase receptor A (TrkA) phosphorylation. Treatment with DOI increased TrkA tyrosine phosphorylation in SK-N-SH cells, determined by immunoprecipitation with TrkA antibody and immunoblotting with anti-phosphotyrosine- and TrkA-antibodies. Analysis of DOI\u2019s effect on individual TrkA residues in SK-N-SH cells showed that it increases TrkA Tyr490 phosphorylation (177\u00a0\u00b1\u00a023% after 5\u00a0\u03bcM DOI for 30\u00a0min compared to vehicle). Furthermore, DOI treatment increased the percentage of SK-N-SH cells extending neurites in a TrkA-dependent manner (17.2\u00a0\u00b1\u00a02.2% after 5\u00a0\u03bcM DOI treatment for 6\u00a0days compared to 5.6\u00a0\u00b1\u00a01.7% after vehicle). In a different cell model\u2014lymphoblastoid cell lines\u2014DOI treatment increased tropomyosin-related kinase receptor B (TrkB) phosphorylation, determined by immunoprecipitation with TrkB antibody and immunoblotting with anti-phosphotyrosine antibody and total Trk antibody. Our results identify the Trk receptors as a downstream target of the hallucinogen DOI. In light of the known involvement of Trk receptors in mental diseases, their participation in DOI-mediated effects warrants further investigation.", 
    "genre": "article", 
    "id": "sg:pub.10.1007/s00702-017-1706-y", 
    "isAccessibleForFree": false, 
    "isFundedItemOf": [
      {
        "id": "sg:grant.5221586", 
        "type": "MonetaryGrant"
      }, 
      {
        "id": "sg:grant.5238123", 
        "type": "MonetaryGrant"
      }
    ], 
    "isPartOf": [
      {
        "id": "sg:journal.1412779", 
        "issn": [
          "0300-9564", 
          "1435-1463"
        ], 
        "name": "Journal of Neural Transmission", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "6", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "124"
      }
    ], 
    "keywords": [
      "SK-N-SH cells", 
      "neurotrophin receptor", 
      "Trk receptors", 
      "TrkA antibody", 
      "effects warrants further investigation", 
      "neurotrophic factor expression", 
      "neuroblastoma SK-N-SH cells", 
      "human neuroblastoma SK-N-SH cells", 
      "effect of DOI", 
      "TrkA tyrosine phosphorylation", 
      "neuronal cell line", 
      "warrants further investigation", 
      "DOI treatment", 
      "deprivation-induced cytotoxicity", 
      "TrkB antibody", 
      "extracellular signal-regulated kinase (ERK) pathway", 
      "signal-regulated kinase pathway", 
      "Trk antibody", 
      "hallucinogen DOI", 
      "neurodegenerative disorders", 
      "factor expression", 
      "TrkA-dependent manner", 
      "tyrosine kinase activity", 
      "receptors", 
      "antibodies", 
      "mental diseases", 
      "cell lines", 
      "anti-phosphotyrosine antibody", 
      "treatment", 
      "further investigation", 
      "downstream targets", 
      "kinase pathway", 
      "B phosphorylation", 
      "hallucinogens", 
      "cells", 
      "current study", 
      "A Phosphorylation", 
      "tyrosine phosphorylation", 
      "phosphorylation", 
      "kinase activity", 
      "immunoprecipitation", 
      "disease", 
      "hydrochloride", 
      "disorders", 
      "depression", 
      "neurites", 
      "effect", 
      "DOI effect", 
      "association", 
      "cytotoxicity", 
      "involvement", 
      "expression", 
      "pathway", 
      "percentage", 
      "promotes", 
      "target", 
      "activity", 
      "study", 
      "manner", 
      "stress", 
      "participation", 
      "lines", 
      "investigation", 
      "DOI", 
      "analysis", 
      "results", 
      "light", 
      "extension", 
      "residues", 
      "dependence"
    ], 
    "name": "The hallucinogen 2,5-dimethoxy-4-iodoamphetamine hydrochloride activates neurotrophin receptors in a neuronal cell line and promotes neurites extension", 
    "pagination": "749-759", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1084023046"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s00702-017-1706-y"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "28315978"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s00702-017-1706-y", 
      "https://app.dimensions.ai/details/publication/pub.1084023046"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-08-04T17:06", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20220804/entities/gbq_results/article/article_729.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1007/s00702-017-1706-y"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s00702-017-1706-y'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s00702-017-1706-y'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s00702-017-1706-y'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s00702-017-1706-y'


 

This table displays all metadata directly associated to this object as RDF triples.

235 TRIPLES      21 PREDICATES      115 URIs      103 LITERALS      23 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s00702-017-1706-y schema:about N09a2d0fae3884b4e9b89085ec410042e
2 N3fa0a14675b64315bfeb4856478030c8
3 N49442cc91c0b41baab46f41d588bc7bb
4 N4b600817f7ae438a8e9d9a5c9a489f3f
5 N4e86fd563d254e528e61f2c17f212ff9
6 N78150e5bee884cd886db7f5957c31fa9
7 N7cb3cd66a35e49539df454c5f31132e9
8 N92aaf0c07e914c058f476adc83e54620
9 N9b59cf0586b74e43831f146107745da6
10 Naea1e3b41c834e4f90504db7359bb976
11 Nb9e1caaa37fa45f1ba3a053674f8daa0
12 Nbcbeded1131646f69022f9f30a1d4136
13 Nd0408edaad2a4f6297346ac3d9e44fd9
14 Ne34a0eb2ae04461eb05c5b2d8db113bf
15 Nf24dbb0b9f364c7ea0428f2891aa9acf
16 Nf8de4021839b4921a4c94d7b80cfa505
17 anzsrc-for:11
18 anzsrc-for:1109
19 schema:author N90ff4371051449f093d875f1411d4b4b
20 schema:citation sg:pub.10.1007/s00018-006-6010-1
21 sg:pub.10.1186/1479-5876-10-239
22 sg:pub.10.1186/gb-2007-8-2-r19
23 sg:pub.10.1385/nmm:1:3:197
24 schema:datePublished 2017-03-18
25 schema:datePublishedReg 2017-03-18
26 schema:description Decreased neurotrophic factors expression and neurotrophin receptors signalling have repeatedly been reported in association with stress, depression, and neurodegenerative disorders. We have previously identified the hallucinogen 2,5-dimethoxy-4-iodoamphetamine hydrochloride (DOI) as protective against trophic deprivation-induced cytotoxicity in human neuroblastoma SK-N-SH cells and established the dependence of this effect on the 5-HT2A receptor, tyrosine kinases activity, and the extracellular signal-regulated kinase pathway. In the current study, we investigated the effect of DOI on tropomyosin-related kinase receptor A (TrkA) phosphorylation. Treatment with DOI increased TrkA tyrosine phosphorylation in SK-N-SH cells, determined by immunoprecipitation with TrkA antibody and immunoblotting with anti-phosphotyrosine- and TrkA-antibodies. Analysis of DOI’s effect on individual TrkA residues in SK-N-SH cells showed that it increases TrkA Tyr490 phosphorylation (177 ± 23% after 5 μM DOI for 30 min compared to vehicle). Furthermore, DOI treatment increased the percentage of SK-N-SH cells extending neurites in a TrkA-dependent manner (17.2 ± 2.2% after 5 μM DOI treatment for 6 days compared to 5.6 ± 1.7% after vehicle). In a different cell model—lymphoblastoid cell lines—DOI treatment increased tropomyosin-related kinase receptor B (TrkB) phosphorylation, determined by immunoprecipitation with TrkB antibody and immunoblotting with anti-phosphotyrosine antibody and total Trk antibody. Our results identify the Trk receptors as a downstream target of the hallucinogen DOI. In light of the known involvement of Trk receptors in mental diseases, their participation in DOI-mediated effects warrants further investigation.
27 schema:genre article
28 schema:isAccessibleForFree false
29 schema:isPartOf Nc43a37877e7d447dba63adf154dd0b1f
30 Nd704946db7604a8e8e47243a7e8912bc
31 sg:journal.1412779
32 schema:keywords A Phosphorylation
33 B phosphorylation
34 DOI
35 DOI effect
36 DOI treatment
37 SK-N-SH cells
38 Trk antibody
39 Trk receptors
40 TrkA antibody
41 TrkA tyrosine phosphorylation
42 TrkA-dependent manner
43 TrkB antibody
44 activity
45 analysis
46 anti-phosphotyrosine antibody
47 antibodies
48 association
49 cell lines
50 cells
51 current study
52 cytotoxicity
53 dependence
54 depression
55 deprivation-induced cytotoxicity
56 disease
57 disorders
58 downstream targets
59 effect
60 effect of DOI
61 effects warrants further investigation
62 expression
63 extension
64 extracellular signal-regulated kinase (ERK) pathway
65 factor expression
66 further investigation
67 hallucinogen DOI
68 hallucinogens
69 human neuroblastoma SK-N-SH cells
70 hydrochloride
71 immunoprecipitation
72 investigation
73 involvement
74 kinase activity
75 kinase pathway
76 light
77 lines
78 manner
79 mental diseases
80 neurites
81 neuroblastoma SK-N-SH cells
82 neurodegenerative disorders
83 neuronal cell line
84 neurotrophic factor expression
85 neurotrophin receptor
86 participation
87 pathway
88 percentage
89 phosphorylation
90 promotes
91 receptors
92 residues
93 results
94 signal-regulated kinase pathway
95 stress
96 study
97 target
98 treatment
99 tyrosine kinase activity
100 tyrosine phosphorylation
101 warrants further investigation
102 schema:name The hallucinogen 2,5-dimethoxy-4-iodoamphetamine hydrochloride activates neurotrophin receptors in a neuronal cell line and promotes neurites extension
103 schema:pagination 749-759
104 schema:productId N34daa5eab2824e44adb37d99f08fbaf1
105 N40041f3db8b841a48826996cf6ece188
106 N72d6c1bfb2b84dcab91408c950e19e8a
107 schema:sameAs https://app.dimensions.ai/details/publication/pub.1084023046
108 https://doi.org/10.1007/s00702-017-1706-y
109 schema:sdDatePublished 2022-08-04T17:06
110 schema:sdLicense https://scigraph.springernature.com/explorer/license/
111 schema:sdPublisher Nf91bf00699334452854592d663f98a32
112 schema:url https://doi.org/10.1007/s00702-017-1706-y
113 sgo:license sg:explorer/license/
114 sgo:sdDataset articles
115 rdf:type schema:ScholarlyArticle
116 N09a2d0fae3884b4e9b89085ec410042e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
117 schema:name Lymphocytes
118 rdf:type schema:DefinedTerm
119 N34daa5eab2824e44adb37d99f08fbaf1 schema:name pubmed_id
120 schema:value 28315978
121 rdf:type schema:PropertyValue
122 N3fa0a14675b64315bfeb4856478030c8 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
123 schema:name Neurites
124 rdf:type schema:DefinedTerm
125 N40041f3db8b841a48826996cf6ece188 schema:name doi
126 schema:value 10.1007/s00702-017-1706-y
127 rdf:type schema:PropertyValue
128 N49442cc91c0b41baab46f41d588bc7bb schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
129 schema:name Cell Line, Tumor
130 rdf:type schema:DefinedTerm
131 N4b600817f7ae438a8e9d9a5c9a489f3f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
132 schema:name Receptor, trkB
133 rdf:type schema:DefinedTerm
134 N4e86fd563d254e528e61f2c17f212ff9 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
135 schema:name Humans
136 rdf:type schema:DefinedTerm
137 N6bdc0051fa8141b288ccb48836a60496 rdf:first sg:person.0736321374.53
138 rdf:rest Ne99231a395244bd6aa700fc533e7ad02
139 N72d6c1bfb2b84dcab91408c950e19e8a schema:name dimensions_id
140 schema:value pub.1084023046
141 rdf:type schema:PropertyValue
142 N78150e5bee884cd886db7f5957c31fa9 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
143 schema:name Hallucinogens
144 rdf:type schema:DefinedTerm
145 N7cb3cd66a35e49539df454c5f31132e9 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
146 schema:name Young Adult
147 rdf:type schema:DefinedTerm
148 N90ff4371051449f093d875f1411d4b4b rdf:first sg:person.0755076545.30
149 rdf:rest N6bdc0051fa8141b288ccb48836a60496
150 N92aaf0c07e914c058f476adc83e54620 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
151 schema:name Phosphorylation
152 rdf:type schema:DefinedTerm
153 N9b59cf0586b74e43831f146107745da6 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
154 schema:name Nerve Growth Factor
155 rdf:type schema:DefinedTerm
156 Naea1e3b41c834e4f90504db7359bb976 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
157 schema:name Serotonin 5-HT2 Receptor Antagonists
158 rdf:type schema:DefinedTerm
159 Nb9e1caaa37fa45f1ba3a053674f8daa0 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
160 schema:name Receptor, trkA
161 rdf:type schema:DefinedTerm
162 Nbcbeded1131646f69022f9f30a1d4136 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
163 schema:name Receptor, Serotonin, 5-HT2B
164 rdf:type schema:DefinedTerm
165 Nc43a37877e7d447dba63adf154dd0b1f schema:volumeNumber 124
166 rdf:type schema:PublicationVolume
167 Nd0408edaad2a4f6297346ac3d9e44fd9 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
168 schema:name Receptor, Serotonin, 5-HT2A
169 rdf:type schema:DefinedTerm
170 Nd704946db7604a8e8e47243a7e8912bc schema:issueNumber 6
171 rdf:type schema:PublicationIssue
172 Ne34a0eb2ae04461eb05c5b2d8db113bf schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
173 schema:name Amphetamines
174 rdf:type schema:DefinedTerm
175 Ne99231a395244bd6aa700fc533e7ad02 rdf:first sg:person.01126412736.07
176 rdf:rest rdf:nil
177 Nf24dbb0b9f364c7ea0428f2891aa9acf schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
178 schema:name Male
179 rdf:type schema:DefinedTerm
180 Nf8de4021839b4921a4c94d7b80cfa505 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
181 schema:name Neuronal Outgrowth
182 rdf:type schema:DefinedTerm
183 Nf91bf00699334452854592d663f98a32 schema:name Springer Nature - SN SciGraph project
184 rdf:type schema:Organization
185 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
186 schema:name Medical and Health Sciences
187 rdf:type schema:DefinedTerm
188 anzsrc-for:1109 schema:inDefinedTermSet anzsrc-for:
189 schema:name Neurosciences
190 rdf:type schema:DefinedTerm
191 sg:grant.5221586 http://pending.schema.org/fundedItem sg:pub.10.1007/s00702-017-1706-y
192 rdf:type schema:MonetaryGrant
193 sg:grant.5238123 http://pending.schema.org/fundedItem sg:pub.10.1007/s00702-017-1706-y
194 rdf:type schema:MonetaryGrant
195 sg:journal.1412779 schema:issn 0300-9564
196 1435-1463
197 schema:name Journal of Neural Transmission
198 schema:publisher Springer Nature
199 rdf:type schema:Periodical
200 sg:person.01126412736.07 schema:affiliation grid-institutes:grid.7400.3
201 schema:familyName Grünblatt
202 schema:givenName Edna
203 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01126412736.07
204 rdf:type schema:Person
205 sg:person.0736321374.53 schema:affiliation grid-institutes:grid.7400.3
206 schema:familyName Walitza
207 schema:givenName Susanne
208 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0736321374.53
209 rdf:type schema:Person
210 sg:person.0755076545.30 schema:affiliation grid-institutes:grid.452327.5
211 schema:familyName Marinova
212 schema:givenName Zoya
213 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0755076545.30
214 rdf:type schema:Person
215 sg:pub.10.1007/s00018-006-6010-1 schema:sameAs https://app.dimensions.ai/details/publication/pub.1046148415
216 https://doi.org/10.1007/s00018-006-6010-1
217 rdf:type schema:CreativeWork
218 sg:pub.10.1186/1479-5876-10-239 schema:sameAs https://app.dimensions.ai/details/publication/pub.1023364217
219 https://doi.org/10.1186/1479-5876-10-239
220 rdf:type schema:CreativeWork
221 sg:pub.10.1186/gb-2007-8-2-r19 schema:sameAs https://app.dimensions.ai/details/publication/pub.1007077528
222 https://doi.org/10.1186/gb-2007-8-2-r19
223 rdf:type schema:CreativeWork
224 sg:pub.10.1385/nmm:1:3:197 schema:sameAs https://app.dimensions.ai/details/publication/pub.1036553133
225 https://doi.org/10.1385/nmm:1:3:197
226 rdf:type schema:CreativeWork
227 grid-institutes:grid.452327.5 schema:alternateName Department of Psychosomatic Medicine, Clinic Barmelweid, 5017, Barmelweid, Switzerland
228 schema:name Department of Child and Adolescent Psychiatry and Psychotherapy, Psychiatric Hospital, University of Zürich, Wagistrasse 12, Schlieren, 8952, Zurich, Switzerland
229 Department of Psychosomatic Medicine, Clinic Barmelweid, 5017, Barmelweid, Switzerland
230 rdf:type schema:Organization
231 grid-institutes:grid.7400.3 schema:alternateName Zürich Center for Integrative Human Physiology, University of Zürich, Zurich, Switzerland
232 schema:name Department of Child and Adolescent Psychiatry and Psychotherapy, Psychiatric Hospital, University of Zürich, Wagistrasse 12, Schlieren, 8952, Zurich, Switzerland
233 Neuroscience Center Zürich, University of Zürich and ETH Zürich, Zurich, Switzerland
234 Zürich Center for Integrative Human Physiology, University of Zürich, Zurich, Switzerland
235 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...